Single nucleotide polymorphism at codon 133 of the RASSF1 gene is preferentially associated with human lung adenocarcinoma risk

Hirotaka Kanzaki, Hiroko Hanafusa, Hiromasa Yamamoto, Yukiko Yasuda, Kazue Imai, Masaaki Yano, Motoi Aoe, Nobuyoshi Shimizu, Kei Nakachi, Mamoru Ouchida, Kenji Shimizu

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The RASSF1 gene, a putative tumor suppressor gene located on human chromosome 3p21, garners much attention for the frequent allelic loss and gene silencing via promoter hypermethylation in a variety of human malignancies. An association between a single nucleotide polymorphism (SNP) at codon 133 of the RASSF1 gene, encoding either alanine (GCT) or serine (TCT), and human cancer risk remains undefined. We therefore, investigated the distribution of the Ala133Ser SNP in 101 patients with lung cancer, 63 with head and neck cancer, 72 with colorectal cancer, 56 with esophageal cancer and 110 healthy controls by polymerase chain reaction and restriction enzyme-digestion assay. The heterozygous Ala/Ser genotype was significantly more frequent in lung cancer patients than in healthy controls (P=0.028). The adjusted odds ratio (OR) for the patients with heterozygous Ala/Ser genotype as compared with the controls with the Ala/Ala genotype was 2.59 (95% confidence interval (CI); 1.11-6.04). The increased risk of the Ala/Ser genotype was found in lung cancer patients but not in other cancer patients we examined. The association was particularly strong in those lung cancer patients of male (adjusted OR; 3.33, 95% CI; 1.37-8.12), with adenocarinoma (adjusted OR; 3.33, 95% CI; 1.36-8.15), early stages (adjusted OR; 3.42, 95% CI; 1.33-8.75) and with smoking habit (adjusted OR; 2.70, 95% CI; 1.06-6.83). These results suggest that the RASSF1 Ala133Ser SNP is associated with development of lung cancer, especially of lung adenocarcinoma. The increased risk of the heterozygous genotype is intriguing, implying a close relation with the dimerization feature of RASSF1 proteins.

Original languageEnglish
Pages (from-to)128-134
Number of pages7
JournalCancer Letters
Volume238
Issue number1
DOIs
Publication statusPublished - Jul 8 2006

Fingerprint

Codon
Single Nucleotide Polymorphism
Lung Neoplasms
Odds Ratio
Genotype
Confidence Intervals
Genes
Neoplasms
Loss of Heterozygosity
Enzyme Assays
Human Chromosomes
Dimerization
Gene Silencing
Esophageal Neoplasms
Head and Neck Neoplasms
Tumor Suppressor Genes
Alanine
Serine
Habits
Adenocarcinoma of lung

Keywords

  • Cancer-predisposition
  • Non-small cell lung cancer (NSCLC)
  • RASSF1
  • SNP
  • Tumor suppressor gene (TSG)

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Single nucleotide polymorphism at codon 133 of the RASSF1 gene is preferentially associated with human lung adenocarcinoma risk. / Kanzaki, Hirotaka; Hanafusa, Hiroko; Yamamoto, Hiromasa; Yasuda, Yukiko; Imai, Kazue; Yano, Masaaki; Aoe, Motoi; Shimizu, Nobuyoshi; Nakachi, Kei; Ouchida, Mamoru; Shimizu, Kenji.

In: Cancer Letters, Vol. 238, No. 1, 08.07.2006, p. 128-134.

Research output: Contribution to journalArticle

Kanzaki, Hirotaka ; Hanafusa, Hiroko ; Yamamoto, Hiromasa ; Yasuda, Yukiko ; Imai, Kazue ; Yano, Masaaki ; Aoe, Motoi ; Shimizu, Nobuyoshi ; Nakachi, Kei ; Ouchida, Mamoru ; Shimizu, Kenji. / Single nucleotide polymorphism at codon 133 of the RASSF1 gene is preferentially associated with human lung adenocarcinoma risk. In: Cancer Letters. 2006 ; Vol. 238, No. 1. pp. 128-134.
@article{18cf0e4e581245eaaa924994c7aa99de,
title = "Single nucleotide polymorphism at codon 133 of the RASSF1 gene is preferentially associated with human lung adenocarcinoma risk",
abstract = "The RASSF1 gene, a putative tumor suppressor gene located on human chromosome 3p21, garners much attention for the frequent allelic loss and gene silencing via promoter hypermethylation in a variety of human malignancies. An association between a single nucleotide polymorphism (SNP) at codon 133 of the RASSF1 gene, encoding either alanine (GCT) or serine (TCT), and human cancer risk remains undefined. We therefore, investigated the distribution of the Ala133Ser SNP in 101 patients with lung cancer, 63 with head and neck cancer, 72 with colorectal cancer, 56 with esophageal cancer and 110 healthy controls by polymerase chain reaction and restriction enzyme-digestion assay. The heterozygous Ala/Ser genotype was significantly more frequent in lung cancer patients than in healthy controls (P=0.028). The adjusted odds ratio (OR) for the patients with heterozygous Ala/Ser genotype as compared with the controls with the Ala/Ala genotype was 2.59 (95{\%} confidence interval (CI); 1.11-6.04). The increased risk of the Ala/Ser genotype was found in lung cancer patients but not in other cancer patients we examined. The association was particularly strong in those lung cancer patients of male (adjusted OR; 3.33, 95{\%} CI; 1.37-8.12), with adenocarinoma (adjusted OR; 3.33, 95{\%} CI; 1.36-8.15), early stages (adjusted OR; 3.42, 95{\%} CI; 1.33-8.75) and with smoking habit (adjusted OR; 2.70, 95{\%} CI; 1.06-6.83). These results suggest that the RASSF1 Ala133Ser SNP is associated with development of lung cancer, especially of lung adenocarcinoma. The increased risk of the heterozygous genotype is intriguing, implying a close relation with the dimerization feature of RASSF1 proteins.",
keywords = "Cancer-predisposition, Non-small cell lung cancer (NSCLC), RASSF1, SNP, Tumor suppressor gene (TSG)",
author = "Hirotaka Kanzaki and Hiroko Hanafusa and Hiromasa Yamamoto and Yukiko Yasuda and Kazue Imai and Masaaki Yano and Motoi Aoe and Nobuyoshi Shimizu and Kei Nakachi and Mamoru Ouchida and Kenji Shimizu",
year = "2006",
month = "7",
day = "8",
doi = "10.1016/j.canlet.2005.07.006",
language = "English",
volume = "238",
pages = "128--134",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Single nucleotide polymorphism at codon 133 of the RASSF1 gene is preferentially associated with human lung adenocarcinoma risk

AU - Kanzaki, Hirotaka

AU - Hanafusa, Hiroko

AU - Yamamoto, Hiromasa

AU - Yasuda, Yukiko

AU - Imai, Kazue

AU - Yano, Masaaki

AU - Aoe, Motoi

AU - Shimizu, Nobuyoshi

AU - Nakachi, Kei

AU - Ouchida, Mamoru

AU - Shimizu, Kenji

PY - 2006/7/8

Y1 - 2006/7/8

N2 - The RASSF1 gene, a putative tumor suppressor gene located on human chromosome 3p21, garners much attention for the frequent allelic loss and gene silencing via promoter hypermethylation in a variety of human malignancies. An association between a single nucleotide polymorphism (SNP) at codon 133 of the RASSF1 gene, encoding either alanine (GCT) or serine (TCT), and human cancer risk remains undefined. We therefore, investigated the distribution of the Ala133Ser SNP in 101 patients with lung cancer, 63 with head and neck cancer, 72 with colorectal cancer, 56 with esophageal cancer and 110 healthy controls by polymerase chain reaction and restriction enzyme-digestion assay. The heterozygous Ala/Ser genotype was significantly more frequent in lung cancer patients than in healthy controls (P=0.028). The adjusted odds ratio (OR) for the patients with heterozygous Ala/Ser genotype as compared with the controls with the Ala/Ala genotype was 2.59 (95% confidence interval (CI); 1.11-6.04). The increased risk of the Ala/Ser genotype was found in lung cancer patients but not in other cancer patients we examined. The association was particularly strong in those lung cancer patients of male (adjusted OR; 3.33, 95% CI; 1.37-8.12), with adenocarinoma (adjusted OR; 3.33, 95% CI; 1.36-8.15), early stages (adjusted OR; 3.42, 95% CI; 1.33-8.75) and with smoking habit (adjusted OR; 2.70, 95% CI; 1.06-6.83). These results suggest that the RASSF1 Ala133Ser SNP is associated with development of lung cancer, especially of lung adenocarcinoma. The increased risk of the heterozygous genotype is intriguing, implying a close relation with the dimerization feature of RASSF1 proteins.

AB - The RASSF1 gene, a putative tumor suppressor gene located on human chromosome 3p21, garners much attention for the frequent allelic loss and gene silencing via promoter hypermethylation in a variety of human malignancies. An association between a single nucleotide polymorphism (SNP) at codon 133 of the RASSF1 gene, encoding either alanine (GCT) or serine (TCT), and human cancer risk remains undefined. We therefore, investigated the distribution of the Ala133Ser SNP in 101 patients with lung cancer, 63 with head and neck cancer, 72 with colorectal cancer, 56 with esophageal cancer and 110 healthy controls by polymerase chain reaction and restriction enzyme-digestion assay. The heterozygous Ala/Ser genotype was significantly more frequent in lung cancer patients than in healthy controls (P=0.028). The adjusted odds ratio (OR) for the patients with heterozygous Ala/Ser genotype as compared with the controls with the Ala/Ala genotype was 2.59 (95% confidence interval (CI); 1.11-6.04). The increased risk of the Ala/Ser genotype was found in lung cancer patients but not in other cancer patients we examined. The association was particularly strong in those lung cancer patients of male (adjusted OR; 3.33, 95% CI; 1.37-8.12), with adenocarinoma (adjusted OR; 3.33, 95% CI; 1.36-8.15), early stages (adjusted OR; 3.42, 95% CI; 1.33-8.75) and with smoking habit (adjusted OR; 2.70, 95% CI; 1.06-6.83). These results suggest that the RASSF1 Ala133Ser SNP is associated with development of lung cancer, especially of lung adenocarcinoma. The increased risk of the heterozygous genotype is intriguing, implying a close relation with the dimerization feature of RASSF1 proteins.

KW - Cancer-predisposition

KW - Non-small cell lung cancer (NSCLC)

KW - RASSF1

KW - SNP

KW - Tumor suppressor gene (TSG)

UR - http://www.scopus.com/inward/record.url?scp=33744919018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744919018&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2005.07.006

DO - 10.1016/j.canlet.2005.07.006

M3 - Article

C2 - 16125301

AN - SCOPUS:33744919018

VL - 238

SP - 128

EP - 134

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1

ER -